Jan 10, 2022 / 02:45PM GMT
Cory William Kasimov - JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst
All right. Thank you, and good morning, everyone. And once again, welcome to the 40th Annual and unfortunately second time Virtual at JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst. And it's my pleasure to introduce our next company, Biogen and CEO, Michel Vounatsos.
Please note that following this presentation, we will move right into the Q&A where you can send in your own questions via the little blue ask a question button on the conference portal, and I'll do my best to work them into the conversation. So Michel, thank you very much for being with us here today. Let me hand things over to you.
Michel Vounatsos - Biogen Inc. - CEO & Director
Thank you, Cory, and good morning, everyone, and thank you for joining us. Before we begin -- next slide. Before we begin, I would like to point out that we'll be making some forward-looking statements. These are based on our current expectations and belief,
Biogen Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers